EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Increased Levothyroxine Requirement After Tirzepatide Initiation

Derya Koç, Miraç Vural Keskinler

AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 677-678

DOI: 10.1016/j.aed.2026.04.007 ↗

Kurz gefasst

Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von Derya Koç und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Türkiye. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonists such as tirzepatide are increasingly used for obesity management. These agents delay gastric emptying and may influence the absorption of orally administered drugs, including levothyroxine. Case Description: A 48-year-old woman with class I obesity (BMI 32 kg/m2) was diagnosed with overt primary hypothyroidism (TSH 17.1 mIU/L; free T4 0.76 ng/dL). Levothyroxine 25 μg/d achieved biochemical normalization. Tirzepatide 2.5 mg weekly was initiated for weight management. Over 3 months, body weight decreased from 116 kg to 100 kg (-13.8%). Despite confirmed adherence and absence of interacting medications, TSH increased to 20.7 mIU/L with low-normal free T4. Levothyroxine dose was increased to 50 μg/d, resulting in TSH suppression (0.33 mIU/L).

Discussion

Weight loss is typically associated with reduced levothyroxine requirements; however, this case demonstrated the opposite pattern. Tirzepatide-induced delay in gastric emptying may have impaired levothyroxine absorption. Previous reports with glucagon-like peptide-1 receptor agonists have mainly described reduced levothyroxine requirements, suggesting that this interaction may be variable and patient-specific.

Conclusion

Levothyroxine requirements may increase in some patients following tirzepatide initiation. Clinicians should consider reassessing thyroid function within 6-8 weeks after starting dual incretin therapy.

Schlagwörter

Stichwörter der Autor:innen

drug interactiongastric emptyinghypothyroidismlevothyroxinetirzepatide

Autor:innen und Institutionen

  • Department of Internal Medicine, Faculty of Medicine, Istanbul Medeniyet University, Istanbul, Türkiye.

Zitieren

APA

Koç, D., & Vural Keskinler, M. (2026). Increased Levothyroxine Requirement After Tirzepatide Initiation. AACE Endocrinology and Diabetes, 13(5), 677-678. https://doi.org/10.1016/j.aed.2026.04.007

Vancouver

Koç D, Vural Keskinler M. Increased Levothyroxine Requirement After Tirzepatide Initiation. AACE Endocrinology and Diabetes. 2026;13(5):677-678. doi:10.1016/j.aed.2026.04.007

BibTeX
@article{Ko2026,
  author = {Koç, Derya and Vural Keskinler, Miraç},
  title = {Increased Levothyroxine Requirement After Tirzepatide Initiation},
  journal = {AACE Endocrinology and Diabetes},
  year = {2026},
  volume = {13},
  number = {5},
  pages = {677--678},
  doi = {10.1016/j.aed.2026.04.007}
}
Kostenlos starten →